SARS‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells

S Lukassen, RL Chua, T Trefzer, NC Kahn… - The EMBO …, 2020 - embopress.org
The SARS ‐CoV‐2 pandemic affecting the human respiratory system severely challenges
public health and urgently demands for increasing our understanding of COVID ‐19 …

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo …

…, M Frankenberger, S Hummler, N Kahn… - The Lancet …, 2021 - thelancet.com
Background Pirfenidone has been shown to slow disease progression in patients with
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …

Combined endoscopic-endobronchial ultrasound-guided fine-needle aspiration of mediastinal lymph nodes through a single bronchoscope in 150 patients with …

FJF Herth, M Krasnik, N Kahn, R Eberhardt, A Ernst - Chest, 2010 - Elsevier
… Author links open overlay panel Felix JF Herth MD, FCCP a , Mark Krasnik MD b , Nicolas
Kahn MD a , Ralf … Dr Kahn: participated in the design of the study and performed procedures. …

The therapy of idiopathic pulmonary fibrosis: what is next?

…, N Chaudhuri, SE Torrisi, N Kahn… - European …, 2019 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease,
characterised by progressive scarring of the lung and associated with a high burden of …

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the …

…, J Kirschner, S Gläser, N Kahn… - European …, 2020 - Eur Respiratory Soc
Objective There is a paucity of observational data on antifibrotic therapy for idiopathic pulmonary
fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and without …

Fibroblast activation protein–specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study

…, O Weinheimer, P Flechsig, N Kahn… - Journal of nuclear …, 2022 - Soc Nuclear Med
Interstitial lung diseases (ILDs) comprise over 200 parenchymal lung disorders. Among
them, fibrosing ILDs, especially idiopathic pulmonary fibrosis, are associated with a poor …

[HTML][HTML] LungPoint—a new approach to peripheral lesions

R Eberhardt, N Kahn, D Gompelmann… - Journal of thoracic …, 2010 - Elsevier
Introduction: Although flexible bronchoscopy is the least invasive procedure for sampling, it
is limited by its inability to reach lesions in the peripheral segments of the lung. Biopsy …

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases

U Oltmanns, N Kahn, K Palmowski, A Träger, H Wenz… - Respiration, 2014 - karger.com
Background: Pirfenidone is a novel antifibrotic drug for the treatment of mild-to-moderate
idiopathic pulmonary fibrosis (IPF). However, adverse events may offset treatment benefits and …

Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung disease

…, S Hirtz, R Agrawal, T Muley, N Kahn… - American journal of …, 2015 - atsjournals.org
Rationale: In many organs, hypoxic cell death triggers sterile neutrophilic inflammation via IL-1R
signaling. Although hypoxia is common in airways from patients with cystic fibrosis (CF), …

[HTML][HTML] The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry

…, JF Meyer, J Kirschner, S Gläser, N Kahn… - Respiratory …, 2019 - Springer
Background Quality of life (QoL) is profoundly impaired in patients with idiopathic pulmonary
fibrosis (IPF). However, data is limited regarding the course of QoL. We therefore analysed …